Search
EU pilot on drug repurposing
Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.
Read moreGoCART coalition activities (CARTs and cellular therapies)
GoCART Clinical Case Discussion Series for Physicians - 4th edition
Panel: Dr. Sara Ghorashian, Dr. Peter Bader and Dr. Franco Locatelli along with moderator Dr.
EHA Congratulates EHA Kick-Off Grant 2021 Winners
The Hague, January 3, 2022 –EHA Congratulates seven talented researchers in Hematology on their receipt of an EHA Kick-Off Grant 2021 after a rigorous selection process.
Read moreFrom Plans to Action: European Cancer Summit
From Plans to Action: European Cancer Summit (Brussels-Hybrid, November 17-18, 2021)
November 17- 18 marks the first anniversary of EHA’s membership to the European Cancer Organisation (ECO), as well as the event dates for the 2021 European Cancer Summit.
The European Hematology Association (EHA) announces an Invitation to Tender (ITT) for PCO services for the EHA Annual Congress
The European Hematology Association (EHA) is pleased to inform the conference and meeting community that it will release an Invitation To Tender (ITT) for the appointment of a Professional Conference Organizer (PCO) for the EHA Congress in 2023.
Read moreShining a Light on Blood Cancer
EHA Launches Digital Campaign
In September 2021, the European Hematology Association (EHA) will honor Blood Cancer Awareness Month with an extensive digital campaign.
The EHA Guidelines Workshop, a meaningful and successful first Series!
November 2020 – April 2021
In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.
Helping steer EHA into the future
In 2020, EHA launched the Taskforce on Diversity, Equity, and Inclusion with an EHA Board mandate.
Read moreT2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
“Complement-ing” positive outcomes during the COVID-19 pandemic
Dr Dimitrios Mastellos (@dmastellos)
The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.